|
| Primary information |
|---|
| ID | 10880 |
| Therapeutic ID | Th1239 |
| Protein Name | Thrombomodulin Alfa |
| Sequence | NA
|
| Molecular Weight | 52124 |
| Chemical Formula | C2230-H3357-N633-O718-S50 |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | 2-3 days after sc injection; 19.82 +/- 2.10 hours after IV injection |
| Description | Thrombomodulin Alfa is a novel, recombinant and soluble thrombomodulin (ART-123). It is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular thromboembolism. |
| Indication/Disease | Investigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis. |
| Pharmacodynamics | Thrombomodulin (TM) alfa, a recombinant human soluble TM, enhances activation of pro-carboxypeptidase B2 (pro-CPB2) by thrombin. Activated pro-CPB2 (CPB2) exerts anti-inflammatory and anti-fibrinolytic activities. |
| Mechanism of Action | Thrombomodulin alfa is a soluble form of recombinant human thrombomodulin comprising all extracellular domains of thrombomodulin. Bound to thrombin, Thrombomodulin alfa inhibits its procoagulant activity and promotes activation of protein C. Thrombomodulin alfa inhibits thrombin generation by the activation of protein C and the subsequent inactivation of factor Va in the presence of protein S. Thrombomodulin alfa attenuates the extension of the clot by inhibiting further thrombin generation on clots, while other anticoagulants inhibit the initiation of clot formation. A higher concentration of Thrombomodulin alfa is needed to affect clotting time and platelet aggregation than thrombin generation. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| NA |
| Clearance | 7-10 days |
| Categories | Amino Acids, Peptides, and Proteins,Carbohydrates,Glycoconjugates,Glycoproteins,Membrane Glycoproteins,Membrane Proteins,Platelet Membrane Glycoproteins,Proteins,Receptors, G-Protein-Coupled,Receptors, Peptide,Receptors, Proteinase-Activated,Receptors, Thrombin |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Prothrombin,Coagulation factor V |
| Brand Name | Recomodulin (in Japan only) |
| Company | Asahi Kasei Pharma Corp |
| Brand Description | Asahi Kasei Pharma Corp |
| Prescribed For | For the treatment of patients with disseminated intravascular cogulation (DIC) |
| Chemical Name | 1-498-thrombomodulin |
| Formulation | NA |
| Physical Appearance | lyophilized powder for solution |
| Route of Administration | Intravenous |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |